Vertex Says Late-Stage Cystic Fibrosis Treatment Studies Meet Endpoint

Vertex Pharmaceuticals said that an experimental treatment combined with its Kalydeco drug significantly improved lung function for a certain type of cystic fibrosis in a pair of Phase 3 studies.



from WSJ.com: US Business http://ift.tt/1jcjSHG

via IFTTT